The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS: Savannah Resources Jumps On Deal With Rio Tinto

Mon, 22nd Jun 2015 10:20

LONDON (Alliance News) - The following stocks are amongst the biggest risers and fallers within the main London indices midday Monday.
-------
FTSE 100 WINNERS
-------
Carnival, up 4.1% at 3,308 pence. Deutsche Bank upgrades Carnival to Buy from Hold, lifting its price target to 3,525p from 3,400p, with the bank saying it expects the second-quarter results from the cruiser operator to be above the upper end of the company's guidance. Analyst Richard Carter says he expects Carnival to demonstrate further booking and pricing recovery coupled with more operational momentum in its Carnival brand.

Sky, up 3.2%. Shares in the broadcaster are higher after the Murdoch family is reported to have rejected bids for its stake in Sky, stoking speculation that they intend to make a new attempt to take full control of the company, the Daily Telegraph reported on Saturday. The most recent bid is understood to have come from Vivendi, the French media conglomerate, while Vodafone Group also made an informal approach for the Murdoch's stake in Sky last year, the newspaper said.

Severn Trent, up 2.9% Canadian investment giant Borealis Infrastructure is considering a GBP5 billion approach for Severn Trent, two years after the FTSE 100 water company rejected an earlier takeover attempt, The Sunday Times reported. The newspaper, citing "sources close to the situation", said it is understood that the two sides opened talks last month, and discussions are at an early stage with no certainty a deal.

Capita, up 2.2%. The outsourcing company said that NHS England has named it as the preferred bidder to establish a single provider framework for administrative support functions for primary care across the UK. Capita said its selection includes an initial contract to manage and deliver services in England. The four-year sole provider framework has a maximum total value of GBP1 billion. Under the framework, the initial contract, which runs for seven to 10 years, for Capita to provide administrative support services for primary care in England is expected to be valued at up to about GBP400 million.
-------
FTSE 100 LOSERS
-------
Randgold Resources, down 1.8%, Fresnillo, down 0.7%. Precious metals miners are amongst the handful of FTSE 100 stocks which are trading lower Monday after the price of gold sunk below USD1,200 an ounce. Gold currently trades at USD1,195.35.
-------
FTSE 250 WINNERS
-------
Spire Healthcare Group, up 9.3%. The private healthcare provider said the major shareholder in South Africa-based private hospital group Mediclinic has acquired a 29.9% stake in the company for GBP432 million. The shareholder, Remgro, has acquired the stake in Spire at 360 pence per share. Spire shares closed at 320 pence on Friday. Spire said the intention is for Mediclinic to acquire the stake in Spire from Remgro in the "near future". Mediclinic and Remgro have confirmed they have no intention to acquiring the rest of Spire.

Bwin.Party Digital Entertainment, up 2.1%. The online gaming operator shares are higher after it said it has agreed to sell its entire interest in World Poker Tour to Ourgame International Holdings for USD35 million in cash. Bwin.party Digital Entertainment said it will continue to sponsor a number of World Poker Tour events and television shows in the US and Europe until the end of December 2016, and will have first refusal on any sponsorship opportunities that could become available until the end of December 2016.
-------
FTSE 250 LOSERS
-------
WS Atkins, down 1.4%. Panmure Gordon downgraded the project designer, engineer and management consultancy to Hold from Buy, saying the current share price does not reflect the near-term risks in its rail business.
-------
AIM ALL-SHARE WINNERS
-------
Savannah Resources, up 85%. The company said it has established a joint venture with mining giant Rio Tinto, which will result in both companies combining their heavy mineral sands projects in Mozambique. Under the deal, Savannah's Mutamba, Dongane and Jangamo prospects, together called the Jangamo project, will be combined with Rio Tinto's Chilubane project. Those prospects border one another and Savannah will operate the joint venture and have the ability to earn up to a 51% stake in the newly combined project by conducting the scoping, pre-feasibility and feasibility studies. Rio Tinto shares are up 0.3%.

Imaginatik, up 38%. The Consultancy and technology products company on Friday said it knows of no reason for the rise in its share price last week. However, it said it is aware that Quob Park Estates has been acquiring shares in the company. It added it has not received a notification of Quob's interest in its shares and has had no contact with the investment vehicle.

Lansdowne Oil & Gas, up 18%. The company said PSE Seven Heads and a subsidiary of PSE Kindsale Energy has entered into a contract with Diamond Offshore Drilling UK for the Ocean Guardian drilling rig to be used to drill a well at the Midleton Prospect in the North Celtic Sea. Kinsale Energy holds an 80% interest in the SEL 4/07 licence, with Lansdowne owning the remaining 20%. PSE Seven Heads is the operator of the licence.

ReNeuron Group, up 12%. The stem cell therapy company said it has extended its existing research collaboration with Australia-based Benitec Biopharma following positive results from early studies conducted by the pair.
-------
AIM ALL-SHARE LOSERS
-------
Armstrong Ventures, off 20%. The investment company said it is "hopeful" about the future, as it said it is operating against tough conditions, which it doesn't see improving in the near term. Chariman Haresh Kanabar said the general market conditions have been difficult for small AIM-listed companies focused on the resources and energy sectors.

Richland Resources, down 13%. The company said it will delay its first sapphire sale to the third quarter of 2015, news which follows a consultation with sightholders. Richland Resources, which is developing the Capricorn Sapphire project, said it will hold a product display and education session on its first recovered sapphires at the time of the Hong Kong Jewellery show from this coming Thursday to Sunday.

By Daniel Ruiz; danielruiz@alliancenews.com; and Neil Thakrar; neilthakrar@alliancenews.com; @NeilThakrar1

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
29 Nov 2019 16:07

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
23 Oct 2019 15:50

ReNeuron presents new data on CTX stem cell platform

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Wednesday that new data relating to its CTX stem cell platform was being presented at the 27th Annual Congress of the European Society of Gene and Cell Therapy in Barcelona.

Read more
23 Oct 2019 09:32

ReNeuron Shares Jump As Lead Cell Line Shows Further Potential

ReNeuron Shares Jump As Lead Cell Line Shows Further Potential

Read more
2 Oct 2019 15:15

ReNeuron Reports Mixed Results For Retinitis Pigmentosa Trial

ReNeuron Reports Mixed Results For Retinitis Pigmentosa Trial

Read more
21 Aug 2019 11:49

ReNeuron boosts scientific advisory board with three appointments

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced the appointment of professor Robert MacLaren, Dr Sally Temple and Dr José-Alain Sahel to its scientific advisory board on Wednesday.

Read more
14 Aug 2019 15:35

ReNeuron's New Cardiff University Venture Gets Research Grant

(Alliance News) - ReNeuron Group PLC on Wednesday said a new venture with Cardiff University has secured a UK government grant to research and develop new treatments for hard-to-target disorders a

Read more
14 Aug 2019 11:16

ReNeuron enters grant-funded partnership with University of Cardiff

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group is partnering with the University of Cardiff under a new grant-funded collaboration utilising its exosome-based drug delivery technology platform, it announced on Wednesday.

Read more
16 Jul 2019 12:16

ReNeuron Secures Patents For Its Exosome Technology Platform

(Alliance News) - ReNeuron Group PLC on Tuesday said it has expanded its intellectual property estate via the grant of patents, covering its exosome technology platform.The cell-based said

Read more
11 Jul 2019 11:36

ReNeuron Annual Loss Narrows On Finance Income And Licence Fee

(Alliance News) - ReNeuron Group PLC on Thursday said its loss narrowed in its most recent financial year after it received an exclusivity fee and increased finance income.Shares in were at

Read more
14 Jun 2019 15:49

ReNeuron wins 'Breakthrough of the Year' at European Mediscience Awards

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group has won the 'Breakthrough of the Year' award at the 2019 European Mediscience Awards, it announced on Friday.

Read more
8 May 2019 11:19

ReNeuron Expects Annual Results In Line With Views After Progress

LONDON (Alliance News) - ReNeuron Group PLC on Wednesday said it expects its annual results to be in line with the board's expectations as it made progress on several clinical cell-based also

Read more
8 May 2019 08:53

ReNeuron advances blindness and stroke therapy candidates

(Sharecast News) - Therapeutics outfit ReNeuron continued to trade in line with expectations throughout its recently wrapped up trading year, advancing both its human retinal progenitor cell therapy candidate and its CTX cell therapy candidate.

Read more
26 Apr 2019 12:09

ReNeuron upbeat on early data from retinitis pigmentosa trials

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced updated positive preliminary data in its ongoing phase 1 and 2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP), on Friday.

Read more
26 Apr 2019 09:58

ReNeuron Reports Positive Test Results For Blindness Treatment Therapy

LONDON (Alliance News) - ReNeuron Group PLC on Friday reported positive trial results for its human retinal progenitor cell therapy candidate for treating blindness-causing disease retinitis in up

Read more
11 Apr 2019 18:24

DIRECTOR DEALINGS: ReNeuron Chair And Other Board Members Buy Shares

LONDON (Alliance News) - ReNeuron Group PLC said a number of directors purchased shares on Thursday, including Non-Executive Chair John Berriman who bought 80,000 shares at 225 pence Thursday, in

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.